Renin–angiotensin system inhibitors and mortality in patients with COVID-19

Luca Rossi¹ · Alessandro Malagoli² · Andrea Biagi¹ · Alessia Zanni¹ · Concetta Sticozzi¹ · Greta Comastri¹ · Luigi Pannone³ · Stefano Gandolfi⁴ · Pasquale Vergara³ · Giovanni Quinto Villani¹

Received: 30 July 2020 / Accepted: 29 October 2020 / Published online: 22 November 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract
Association of renin–angiotensin system inhibitors with risk of death in patients with hypertension (HTN) and coronavirus disease 2019 (COVID-19) is not well characterized. The aim of this study was to evaluate the outcomes of patients with HTN and COVID-19 with respect to different chronic antihypertensive drug intake. We performed a retrospective, observational study from a large cohort of patients with HTN and with a laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection admitted to the Emergency Rooms (ER) of the Piacenza Hospital network from February 21, 2020 to March 20, 2020. There were 1050 patients admitted to the ERs of the Piacenza Hospital network with COVID-19. HTN was present in 590 patients [median age, 76.2 years (IQR 68.2–82.6)]; 399 (66.1%) patients were male. Of them, 248 patients were chronically treated with ACEi, 181 with ARBs, and 161 with other drugs (O-drugs) including beta blockers, diuretics and calcium-channel inhibitors. With respect to the antihypertensive use, there was no difference between comorbid conditions. During a follow-up of 38 days (IQR 7.0–46.0), 256 patients (43.4%) died, without any difference stratifying for antihypertensive drugs. Of them, 107 (43.1%) were in ACEi group vs 67 (37%) in ARBs group vs 82 (50.7%) in O-drugs group, (log-rank test: \( p = 0.066 \)). In patients with HTN and COVID-19, neither ACEi nor ARBs were independently associated with mortality. After adjusting for potential confounders in risk prediction, the rate of death was similar. Our data confirm Specialty Societal recommendations, suggesting that treatment with ACEIs or ARBs should not be discontinued because of COVID-19.

Keywords COVID-19 · SARS-CoV-2 · Renin–angiotensin system (RAS) inhibitors · Mortality · Hypertension

Abbreviations
ACE2 Angiotensin-converting enzyme 2
ACEi Angiotensin-converting enzyme inhibitors
ARBs Angiotensin-receptor blockers
COVID-19 Coronavirus disease 2019
ER Emergency rooms
HTN Hypertension
O-drugs Other drugs
RAS Renin–angiotensin system
RT-PCR Reverse transcription polymerase chain reaction
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

Luca Rossi and Alessandro Malagoli equally contributed to the manuscript and should be considered as shared first authors.

Pasquale Vergara and Giovanni Quinto Villani equally contributed to the manuscript and should be considered as shared last authors.

* Alessandro Malagoli
ale.malagoli@gmail.com

1 Division of Cardiology, Cardiovascular and Emergency Department, Guglielmo da Saliceto Hospital, Piacenza, Italy
2 Division of Cardiology, Nephro-Cardiovascular Department, “S. Agostino-Estense” Public Hospital, University of Modena and Reggio Emilia, 1355, Via Pietro Giardini - Baggiovara, 41126 Modena, Italy
3 Arrhythmia Unit and Electrophysiology Laboratories, San Raffaele Hospital, Milano, Italy
4 Health Management, Guglielmo da Saliceto Hospital, ASL Piacenza, Piacenza, Italy
Introduction

In late December 2019, the coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was described for the first time in Wuhan, China [1]. Quickly spreading all over the world, it was declared a pandemic infection by the World Health Organization on March 11, 2020 [2]. The clinical spectrum of COVID-19 appeared to be wide, encompassing asymptomatic infection, mild upper respiratory tract illness and acute respiratory distress syndrome, with a high mortality rate [3, 4]. It remains unclear whether the reported mortality was related to the chronic use of renin–angiotensin system (RAS) inhibitors. Angiotensin-Converting Enzyme inhibitors (ACEi) and Angiotensin-Receptor Blockers (ARBs) are a group of pharmaceuticals that have different effects on angiotensin II, the primary substrate of the angiotensin-converting enzyme 2 (ACE2), commonly applied in the treatment of hypertension (HTN). The potential bridge between SARS-CoV-2 pathophysiology and ACEi/ARBs effects derives from evidences showing that SARS-CoV-2 uses ACE2 receptor to enter in human alveolar epithelial cells [5]. ACE2 is a homologue of ACE, widely distributed in the heart, kidneys and lungs, and it functions as a negative regulator of the RAS. Use of ACEIs and ARBs might upregulate ACE2 expression, thus increasing patient susceptibility to viral host cell entry. The purpose of the present study was to evaluate the association of ACEi and ARBs with risk of death in patients with HTN and COVID-19.

Statistical methods

Data collection

Clinical data are routinely collected during ER access and hospitalization in Piacenza Hospital network on a shared electronic medical record. Deaths in Piacenza Province are collected on a daily basis from the “Azienda Sanitaria Locale” (Local Health Authority) and recorded on an electronic survival record. Clinical data were extracted from the electronic medical records and merged with the survival data provided by the Azienda Sanitaria Locale by members of the research team; data were carefully reviewed and confirmed by two independent researchers to guarantee the accuracy of the data extraction procedures. Patients were followed up from the index date and until 1 of the following: outcome occurrence or end of study period (April 24, 2020). The endpoint of the study was death for any cause.

Methods

Study design and population

This was a retrospective observational study performed at Piacenza Hospital Network, including 3 Hospitals in Piacenza Province, Italy (‘Guglielmo da Saliceto’ Piacenza Hospital, Castel San Giovanni Hospital and Fiorenzuola d’Arda Hospital); the Hospital network is referral for 287 152 inhabitants. All consecutive patients with laboratory-confirmed COVID-19 infection admitted to the Emergency Rooms (ER) of the Piacenza Hospital network from February 21, 2020 to March 20, 2020 and HTN were enrolled in the study. Clinical investigations were conducted according to the principles of the Declaration of Helsinki. The study was approved by the Institutional Ethical Board of the “Emilia Nord Area” (Approval number 2020/0029787); written informed consent was waived by the Ethics Commission due to the emergency of the infectious disease. Positive laboratory test for SARS-Cov-2 infection was defined as a result of real-time reverse transcription polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs [6]. The exam was implemented in a local laboratory with the adjunct of RT-PCR assays. Patients with HTN were classified based upon documented medical history with systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg [7].
matching and a ratio of 1:1:1. The balance of covariates was evaluated by estimating standardized differences before and after matching, and small absolute value less than 0.25 was considered successful balancing between the groups. Malignancies included active neoplasia and history of any previous neoplasia; cardiovascular disease included cardiomyopathy and heart failure. Analyses regarding different factors were based on non-missing data. Analyses were performed using SPSS statistical software version 23.0 (IBM SPSS); significance level was set at 0.05.

Results

Patients characteristics

As of February 21, 2020 to March 20, 2020, 1,050 consecutive patients with confirmed SARS-CoV2 infection were admitted to the ERs of Piacenza Hospital network. Among these patients, a total of 603 had a history of HTN. After excluding 13 patients without available key information in their medical records, we included 590 patients in the final analysis. Clinical data of patients are shown in Table 1. The median age was 76.2 years (IQR 68.2–82.6) ranging from 33.8 to 98.5 years; 399 (66.1%) were male. 90 (15.2%) were discharged from the ER and treated in the outpatient setting. 500 (84.8%) were admitted into the hospital: of these patients, 84 patients (14.2%) have had access to the intensive care unit and 133 (22.5%) were admitted in semi-intensive care units. The median time from illness onset to hospital admission was 7 days (IQR 3–10). One-third of the patients required respiratory support with invasive mechanical ventilation (76, 12.9%) or with non-invasive ventilation (119, 19.2%). Non-survivor patients were older [72.9 years old (IQR 64.1–80.2) vs 79.5 years old (IQR 73.9–84.8), \( p < 0.001 \)] and showed more comorbidities compared to survivors. Moreover, a greater female sex prevalence was observed in survivor patients (63.5% vs 73.0%, \( p = 0.01 \)).

Characteristics of antihypertensive drug treatment groups

248 (42.0%) patients chronically used ACEi, 181 (30.7%) ARBs, and 161 (27.3%) O-drugs; their clinical data are shown in Table 2. Users of ACEi/ARBs trended to be younger than non-users (75.6 years [IQR 66.8–81.3] vs 76.6 years [IQR 69.7–84.6]) and were more often men than non-users. Underlying diseases were present in nearly half of patients, with hyperlipidemia being the most common, followed by diabetes, cardiovascular disease, chronic kidney disease and stroke. As a result, 240 (40.7%) patients had 3 or more coexisting medical conditions, without significant differences between groups.

The most common self-reported symptoms at onset of illness were fever and dyspnea, followed by cough, and fatigue; less common symptoms were sputum production, sputum production, and headache. More than half of patients (60.7%) developed dyspnea. Symptoms were not different between groups. COVID-19 severity was classified according to the guidelines on the Diagnosis and Treatment of COVID-19 [8] and defined as severe with the presence of one of the following conditions: respiratory failure that require mechanical ventilation, shock or multi-organ dysfunction. Critical clinical conditions were not different between groups.

Outcome analysis

At the end of the study period, 228 (38.6%) patients were discharged, 16 (2.7%) patients were still hospitalized, and 256 (43.4%) patients died. All 90 patients treated in the outpatient setting were alive. The median time from illness onset to death was 12.5 days (IQR 4.5–16.0). In Cox proportional hazard modeling, age (hazard ratio: 1.059; 95% confidence interval: 1.045–1.073; \( p < 0.001 \)) and gender (hazard ratio: 0.699; 95% confidence interval: 0.531–0.922; \( p = 0.011 \)) were associated with death; likewise, the PaO2/FiO2, the respiratory rate, LDH and PCR serum levels were found strong mortality predictors. Chronic intake of various antihypertensive drug treatments was not associated with risk of death. None of the comorbidities was related with mortality, whereas the coexistence of 3 or more underlying diseases was a predictor of mortality (Table 3). No significant differences in mortality were found between groups (log-rank test: \( p = 0.066 \)). Mortality was 43.1% among ACEi users, 37.0% among ARBs users, and 50.9% among patients using any other antihypertensive drug, with a hint at possible longer survival in patients on ACEi or ARBs treatment (Fig. 1). We conducted a propensity score-matched analysis to account for unbalances in the following variables: age, gender, diabetes and chronic kidney disease. 159 patients on ACEi were successfully matched with 163 patients on ARBs and 149 on O-Drugs. After matching, no significant differences in mortality were found between ACEi, ARBs, and O-drugs groups (log-rank test: \( p = 0.102 \)). Kaplan–Meier curve for the three drug treatments after matching is shown in Fig. 2.

Discussion

In the current study, data showed that RAS inhibitors were not associated with an increased mortality of COVID-19 in patient with HTN.

As China has firstly experienced the outbreak of COVID-19, the current available epidemiological data
1 Of interest, HTN was the most frequent coexisting condition, with an estimated prevalence of 15%; however, data from PEACE Million Persons Project showed that nearly half of Chinese adults are suffering from HTN [10]. In contrast to these findings, the prevalence of HTN in our data is significantly higher, reflecting the real rate of HTN in the general population.

Recently, uncertainties have been raised on the use anti-hypertensive drugs that modulate the RAS in patient at risk for COVID-19; it has been suggested that they could act as a potential risk factor for poor outcome in COVID-19 patients by up-regulating ACE2. The importance of RAS in the mechanisms that cause HTN and determine its prognosis is well established. Angiotensin II is the principal mediator

Table 1 Characteristics of patients with hypertension and COVID-19

|                          | All population | Survivors | Non survivors | p value |
|--------------------------|----------------|-----------|---------------|---------|
| Age—median (IQR) (years)| 76.2 (68.2–82.6)| 72.9 (64.1–80.2)| 79.5 (73.9–84.8)| <0.001 |
| Male gender no. (%)     | 399 (67.6)     | 212 (63.5) | 187 (73.0)    | 0.014   |
| Chronic disease         |                |           |               |         |
| Cardiovascular disease—no. (%) | 95 (16.1)     | 50 (15.0) | 45 (17.6)    | 0.393   |
| Hyperlipidemia—no. (%)  | 205 (34.7)     | 113 (33.8) | 92 (35.9)    | 0.595   |
| Diabetes—no. (%)        | 137 (23.2)     | 70 (21.0)  | 67 (26.2)    | 0.137   |
| Atrial fibrillation—no. (%) | 101 (17.1)   | 49 (14.7) | 52 (20.3)    | 0.071   |
| COPD—no. (%)            | 121 (20.5)     | 69 (20.7)  | 52 (20.3)    | 0.918   |
| CKD—no. (%)             | 90 (15.3)      | 32 (9.6)   | 58 (22.7)    | <0.001  |
| Stroke—no. (%)          | 21 (3.6)       | 8 (2.4)    | 13 (5.1)     | 0.081   |
| Malignancy—no. (%)      | 47 (8.0)       | 23 (6.9)   | 24 (9.4)     | 0.269   |
| 3 or more comorbidities—no. (%) | 240 (40.7) | 124 (37.1) | 116 (45.3)  | 0.045   |
| Respiratory support     |                |           |               |         |
| OTI—no. (%)             | 76 (12.9)      | 47 (14.1) | 29 (11.3)    | 0.324   |
| NIV—no. (%)             | 113 (19.2)     | 37 (11.1)  | 76 (29.7)    | <0.001  |
| Symptoms at onset of illness |            |           |               |         |
| Fever—no. (%)           | 450 (76.3)     | 231 (69.1) | 219 (85.5)   | 0.550   |
| Cough—no. (%)           | 227 (38.5)     | 138 (41.3) | 89 (34.8)    | 0.001   |
| Dyspnea—no. (%)         | 358 (60.7)     | 171 (51.2) | 187 (73.0)   | 0.058   |
| Diarrhea—no. (%)        | 37 (6.3)       | 26 (7.8)   | 11 (4.3)     | 0.010   |
| Vital signs at admission|                |           |               |         |
| Temperature (°C)—median (IQR) | 37.5 (36.8–38.3) | 37.4 (36.8–38.2) | 37.5 (36.7–38.3) | 0.934 |
| SBP (mmHg)—median (IQR) | 130.0 (115.0–145.0) | 130.0 (120.0–147.5) | 130 (113.5–145.0) | 0.394 |
| PaO2/FiO2—median (IQR)  | 238.1 (152.4–290.5) | 263.9 (211.3–302.3) | 200.0 (112.9–279.4) | <0.001 |
| PaO2/FiO2 < 300—no. (%) | 375 (63.3)     | 164 (49.1) | 211 (82.8)   | <0.001  |
| Laboratory parameters—median (IQR) |            |           |               |         |
| Serum creatinine (mg/dL) | 1.1 (0.9–1.6) | 1.0 (0.9–1.3) | 1.3 (1.0–1.8) | <0.001 |
| LDH (U/L)               | 413.0 (305.0–537.0) | 385.0 (297.0–486.0) | 462.0 (338.0–601.5) | <0.001 |
| C-reactive protein (mg/dL) | 11.3 (5.8–17.5) | 9.9 (5.0–15.5) | 12.9 (7.2–19.3) | <0.001 |
| Hemoglobin (g/dL)       | 13.4 (12.0–14.7) | 13.6 (12.5–14.8) | 13.1 (11.6–14.6) | 0.025 |
| White blood cell count (10³/L) | 6.9 (5.2–9.3) | 6.6 (5.0–8.9) | 7.2 (5.6–10.1) | 0.019 |
| Lymphocytes (%)         | 11.9 (6.4–17.9) | 13.4 (7.8–19.3) | 9.7 (5.4–16.6) | <0.001 |
| Pneumonia classification|                |           |               |         |
| COVID severe—no. (%)    | 229 (38.8)     | 40 (12.0)  | 189 (73.8)   | <0.001  |
| Curb 65 severe—no. (%)  | 100 (16.9)     | 44 (13.2)  | 56 (21.9)    | 0.005   |
| qSOFA severe—no. (%)    | 59 (10.0)      | 39 (11.7)  | 20 (7.8)     | 0.121   |

IQR, interquartile range. COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, OTI orotracheal intubation, NIV non-invasive ventilation, SBP systolic blood pressure, PaO2/FiO2 partial pressure of oxygen in arterial blood/fraction of inspired oxygen, LDH lactate dehydrogenase, qSOFA quick sequential organ failure assessment.
of RAS. ACEi and ARBs are the major classes of RAS inhibitors and have been proved to reduce cardiovascular mortality [11, 12]. Both classes of drugs block the actions of angiotensin II and interact with ACE2 by different mechanisms. ACE2 has been found to be protective in a number of different lung injury models and it seems reasonable that RAS inhibitors should increase ACE2 level in human lungs [13, 14]. SARS-CoV-2 interfaces with RAAS through ACE2 [15]. It has been shown that SARS-CoV-2 uses ACE2 for entry into target cells [16]. Moreover, SARS-CoV-2 spike protein binding to ACE2 downmodulates ACE2 expression, and loss of ACE2 expression results in excessive production of angiotensin. Given the dual possible role of ACE2 in COVID-19, two opposite hypotheses were formulated: the first emphasizes the ability of SARS-CoV-2 to use ACE2 for entry into target cells. On the basis of this detrimental effect,

### Table 2 Clinical characteristics of patients on treatment with ACEi, ARBs and other drugs

|                           | ACEi | ARBs | O-drugs |
|---------------------------|------|------|---------|
|                          | 248  | 181  | 161     |
| Age—median (IQR) (years)  | 76.3 (68.8–82.7) | 75.2 (66.8–81.3) | 76.6 (69.7–84.6) |
| Male gender no. (%)       | 187 (75.4) | 120 (66.3) | 92 (57.1) |
| Chronic disease           |      |      |         |
| Cardiovascular disease—no. (%) | 43 (17.3) | 23 (12.7) | 29 (18.0) |
| Hyperlipidemia—no. (%)    | 86 (34.7) | 70 (38.7) | 49 (30.4) |
| Diabetes—no. (%)          | 63 (25.4) | 47 (26.0) | 27 (16.8) |
| Atrial fibrillation—no. (%) | 45 (18.1) | 31 (17.1) | 25 (15.5) |
| COPD—no. (%)              | 40 (16.1) | 47 (26.0) | 34 (21.1) |
| CKD—no. (%)               | 41 (16.5) | 25 (13.8) | 24 (14.9) |
| Stroke—no. (%)            | 11 (4.4) | 6 (3.3) | 4 (2.5) |
| Malignancy—no. (%)        | 22 (8.9) | 13 (7.2) | 12 (7.5) |
| 3 or more comorbidities—no. (%) | 101 (40.7) | 78 (43.1) | 61 (37.9) |
| Respiratory support       |      |      |         |
| OTI—no. (%)               | 34 (13.7) | 22 (12.2) | 20 (12.4) |
| NIV—no. (%)               | 50 (20.2) | 39 (21.5) | 24 (14.9) |
| Symptoms at onset of illness |      |      |         |
| Fever—no. (%)             | 188 (75.8) | 137 (75.7) | 125 (77.6) |
| Cough—no. (%)             | 105 (42.3) | 67 (37.0) | 55 (34.2) |
| Dyspnea—no. (%)           | 159 (64.1) | 108 (59.7) | 91 (56.5) |
| Diarrhea—no. (%)          | 17 (6.9) | 9 (5.0) | 11 (6.8) |
| Vital signs at admission  |      |      |         |
| Temperature (°C)—median (IQR) | 37.7 (36.9–38.4) | 37.3 (36.6–38.0) | 37.5 (37.0–38.1) |
| SBP (mmHg)—median (IQR)   | 130.0 (117.5–150.0) | 125.0 (114.5–138.0) | 127.5 (115.0–144.0) |
| PaO2/FiO2—median (IQR)    | 223.5 (151.8–281.5) | 226.4 (167.3–290.5) | 257.1 (137.6–304.0) |
| PaO2/FiO2 < 300—no. (%)   | 168 (67.7) | 114 (63.0) | 93 (57.8) |
| Laboratory parameters—median (IQR) |      |      |         |
| Serum creatinine (mg/dL)  | 1.1 (0.9–1.6) | 1.2 (0.9–1.5) | 1.1 (0.9–1.7) |
| LDH (U/L)                 | 425.0 (314.5–540.0) | 437.0 (326.5–574.8) | 364.5 (288.8–482.0) |
| C-reactive protein (mg/dL) | 10.9 (5.7–16.8) | 12.0 (6.2–18.4) | 10.9 (5.4–18.5) |
| Hemoglobin (g/dL)         | 13.4 (12.1–14.9) | 13.6 (12.4–14.7) | 13.2 (11.8–14.5) |
| White blood cell count (10^3/L) | 6.7 (5.2–9.2) | 7.3 (5.5–10.0) | 6.7 (5.2–8.8) |
| Lymphocytes (%)           | 12.6 (5.7–18.4) | 11.6 (6.7–16.7) | 11.3 (6.7–17.9) |
| Pneumonia classification  |      |      |         |
| Covid severe—no. (%)      | 99 (39.9) | 72 (39.8) | 58 (36.0) |
| Curb 65 severe—no. (%)    | 43 (17.3) | 29 (16.0) | 28 (17.4) |
| qSOFA severe—no. (%)      | 32 (12.9) | 14 (7.7) | 13 (8.1) |

ACEi angiotensin-converting enzyme inhibitors, ARBs angiotensin-receptor blockers, IQR interquartile range, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, OTI orotracheal intubation, NIV non-invasive ventilation, SBP systolic blood pressure, PaO2/FiO2 partial pressure of oxygen in arterial blood/fraction of inspired oxygen, LDH lactate dehydrogenase, qSOFA quick sequential organ failure assessment.
some experts have postulated that use of ACEi/ARBs could increase risk for or severity of COVID-19, suggesting the withdrawal of these drugs [17]. The second hypothesis highlights the protective role of ACE2 on lung injury by reducing angiotensin II level. It has been postulated that unabated angiotensin II may be in part responsible for organ injury in COVID-19 [15], suggesting potential for benefit rather than harm of pharmacological regulation of ACE2 expression. Both hypotheses are based on few data, and observational studies have not yielded compelling data on whether COVID-19 patients who take these drugs fare better or worse than otherwise similar patients. Experimental animal models and studies in humans have shown mixed findings with respect to the effects of RAS inhibition on ACE2 levels or activity in tissue. Unfortunately, data regarding the effects of RAS inhibitors on lung-specific expression of ACE2 are lacking. Recently, Zhang et al. [18] reported the outcomes of hospitalized COVID-19 patients with HTN stratified by RAS inhibitors in-hospital intake. In this retrospective inpatient study, use of ACEi/ARBs was associated with lower risk of all-cause mortality compared with ACEi/ARBs non-users. Feng Y et al. [19] found a significant difference in ACEi/ARBs usage among COVID-19 patients with different severities, according to the Chinese guidelines on diagnosis and treatment of COVID-19. Our findings were consistent with these results: the use of ACEi or ARBs was not associated with a detrimental effect on mortality, as compared with patients treated with other antihypertensive drugs.

**Clinical implications**

Despite the theoretical uncertainties regarding whether RAS inhibition may influence the infectivity of SARS-CoV-2, there are few available evidences about switching from a RAS inhibitor to another antihypertensive therapy in patients with known or suspected COVID-19. Moreover, a high number of HTN patients solicited therapy changes or interruption during on-going pandemic. Changes in antihypertensive drug treatment require dose titration and potentially exposes patients to the side effects related to the

---

**Table 3** Cox regression analysis of factors associated with mortality

|                          | HR    | 95% CI          | p value |
|--------------------------|-------|-----------------|---------|
| Age                      | 1.059 | 1.045–1.073     | <0.001  |
| Gender                   | 0.699 | 0.531–0.922     | 0.011   |
| Vital signs at admission |       |                 |         |
| Temperature              | 0.990 | 0.870–1.126     | 0.882   |
| PaO2/FiO2                | 0.995 | 0.994–0.997     | <0.001  |
| PaO2/FiO2 < 300          | 3.519 | 2.549–4.859     | <0.001  |
| Laboratory parameters    |       |                 |         |
| LDH                      | 1.001 | 1.000–1.001     | <0.001  |
| C-reactive protein       | 1.018 | 1.011–1.025     | <0.001  |
| White blood cell count   | 1.044 | 1.015–1.074     | 0.003   |
| Lymphocytes rate         | 0.971 | 0.956–0.985     | <0.001  |
| Chronic diseases         |       |                 |         |
| Cardiovascular disease   | 1.180 | 0.855–1.628     | 0.314   |
| Hyperlipidemia           | 1.108 | 0.859–1.431     | 0.429   |
| Diabetes                 | 1.233 | 0.933–1.629     | 0.142   |
| Atrial fibrillation      | 1.390 | 0.925–1.885     | 0.134   |
| COPD                     | 1.012 | 0.746–1.372     | 0.939   |
| CKD                      | 1.565 | 0.988–1.983     | 0.066   |
| Stroke                   | 1.721 | 0.985–3.008     | 0.056   |
| Malignancy               | 1.306 | 0.858–1.989     | 0.213   |
| 3 or more comorbidities  | 1.322 | 1.034–1.692     | 0.026   |
| Chronical drugs intake   |       |                 |         |
| ACEi                     | 0.993 | 0.775–1.273     | 0.956   |
| ARBs                     | 0.771 | 0.584–1.019     | 0.068   |
| CCBs                     | 0.951 | 0.736–1.229     | 0.702   |
| Alpha blockers           | 1.180 | 0.797–1.746     | 0.410   |
| Diuretics                | 1.466 | 1.003–1.882     | 0.063   |
| Beta blockers            | 1.171 | 0.916–1.497     | 0.207   |

*HR* hazard ratio, *PaO2/FiO2* partial pressure of oxygen in arterial blood/fraction of inspired oxygen, *LDH* lactate dehydrogenase, *COPD* chronic obstructive pulmonary disease, *CKD* chronic kidney disease, *ACEi* angiotensin-converting enzyme inhibitors, *ARBs* angiotensin-receptor blockers, *CCBs* calcium-channel blockers

---

**Fig. 1** Kaplan–Meier event curves reported the mortality between groups stratified by the antihypertensive drug treatment. No differences between ARBs, ACEi or O-drugs treatment were found. *ARBs* angiotensin-receptor blockers, *ACEi* angiotensin converting enzyme inhibitors, *O-drugs* other drugs, including Beta-blockers, Calcium channels blockers, Alfa-blockers, and Diuretics.
new regimen; the risk of SARS-CoV-2 exposure related to the transient lockdown interruption for face-to-face visits should not be neglected. Accordingly, several Specialty Societies strongly recommended to continue RAS inhibitors in patients in otherwise stable condition who are at risk for, are being evaluated for, or have COVID-19. Our data confirm this statement, suggesting that treatment with ACEi or ARBs should not be discontinued because of COVID-19.

Strengths and limitations

This study was a retrospective observational analysis of data from a Hospital Network of a single Province in Italy. It is plausible that the effects of ACEi/ARBs may be different among patients in ethnically or geographically diverse populations. Moreover, we did not account for socioeconomic status. However, large sample size with absence of missing values for collected variables and long-term follow-up is a major strength. Since the study was underpowered to detect any differential effect between ACEi and ARBs, future bigger observational studies and on-going prospective randomized trials are advisable to fully elucidate possible protective effects of those drug treatments [20–23].

Conclusions

In summary, in patients with hypertension, Angiotensin-Converting Enzyme inhibitors and Angiotensin-Receptor Blockers are not associated with mortality of COVID-19. Our data confirm Specialty Societal recommendations, suggesting that treatment with renin–angiotensin system inhibitors should not be discontinued or replaced with other antihypertensive drugs because of COVID-19.

Compliance with ethical standards

Conflict of interest The authors report no conflicts.

References

1. WHO. Novel coronavirus—China. Jan 12, 2020. 2020; https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/. Accessed 15 April 2020.
2. WHO. Director-General’s opening remarks at the media briefing on COVID-19: 11 March 2020. Published March 11, 2020. 2020; https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19---11-march-2020. Accessed 16 April 2020.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrier T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.
6. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. January 28, 2020. 2020. Accessed 5 March 2020.
7. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;36:1953–2041.
8. National Health Commission of the People’s Republic of China Diagnosis and treatment protocol for COVID-19 (trial version 7) 2020. https://www.chinadaily.com.cn/pdf/2020/1.Clinical.Protocols.for.the.Diagnosis.and.Treatment.of.COVID-19.V7.pdf.
9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
10. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PACE Money Persons Project). Lancet. 2017;390:2549–58.
11. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71:1474–82.
12. Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 2017;103:1339–46.
13. Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234.
14. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970–6.
15. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90.
16. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–9.
17. Sommerstein R, Kochen MM, Messerli FH, Grani C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020;9:e016509.
18. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671–81.
19. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020;201:1380–8.
20. Lopes RD, Macedo AV, Melo de Barros e Silva PG, Junqueira-Moll-Bernardes R, Feldman A, SabaArruda GD, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—The BRACE CORONA Trial. Am Heart J. 2020;226:49–59.
21. ClinicalTrials.gov. Coronavirus (COVID-19) ACEi/ARB investigation (CORONACION). ClinicalTrials.gov identifier: NCT04330300. https://clinicaltrials.gov/ct2/show/NCT04330300. Accessed 10 June 2020.
22. ClinicalTrials.gov. ACE inhibitors or ARBs discontinuation in context of SARS-CoV-2 pandemic (ACORES-2). ClinicalTrials.gov identifier: NCT04329195. https://clinicaltrials.gov/ct2/show/. Accessed 10 June 2020.
23. ClinicalTrials.gov. Losartan for patients with COVID-19 not requiring hospitalization. ClinicalTrials.gov identifier: NCT04311177. https://clinicaltrials.gov/ct2/show/NCT04311177. Accessed 10 June 2020.